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Introduction: To	compare	 the	outcomes	of	women	who	were	 initially	managed	by	
intrauterine	balloon	tamponade	or	uterine	artery	embolization	because	of	persistent	
postpartum	hemorrhage	demanding	an	immediate	intervention	to	control	bleeding.
Material and methods: Propensity	 score‐matched	 cohort	 study	 including	 women	
who	 had	 intrauterine	 balloon	 tamponade	 or	 uterine	 artery	 embolization	 as	 initial	
management	strategy	to	control	persistent	postpartum	hemorrhage,	that	is,	refrac‐
tory	to	first‐line	therapy	combined	with	at	least	one	uterotonic	agent.	The	primary	





bolization	at	 a	blood	 loss	between	1000	and	7000	mL.	There	was	no	 statistically	
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1  | INTRODUC TION
Postpartum	hemorrhage	remains	the	leading	cause	of	maternal	mor‐








tamponade,	 uterine	 compression	 sutures	 and	 devascularization	 of	
the	uterine	artery	by	surgical	ligation	or	radiological	embolization.6




tion	 syndrome,	 thrombo‐embolic	 events	 or	 uterine	 necrosis).7‐10 On 
the	 other	 hand,	 intrauterine	 balloon	 tamponade	 has	 emerged	 as	 an	
inexpensive	and	 less	 invasive	option	to	control	ongoing	bleeding.11‐13 
Insertion	of	an	intrauterine	balloon	for	the	purpose	of	tamponade	during	




















































This	 study	 used	 data	 from	 the	 Transfusion	 strategies	 in	 women	
during	 Major	 Obstetric	 Haemorrhage	 study	 (TeMpOH‐1).	 The	
TeMpOH‐1	 study	was	 a	 nationwide	 retrospective	 cohort	 study	 in	
61	 hospitals	 in	 the	Netherlands	 (71%	of	 all	 hospitals	 in	 the	 coun‐
try)	in	which	data	from	medical	files	of	pregnant	women	of	at	least	
18	years	old	were	included.	These	women	had	received	at	least	four	
units	 of	 packed	 red	 blood	 cells	 or	 any	 transfusion	 of	 fresh	 frozen	
plasma	and/or	platelets	in	addition	to	packed	red	blood	cells	because	
of	obstetric	hemorrhage	(≥1000	mL	blood	loss	during	pregnancy	or	
the	 first	24	hours	 following	birth)	between	1	 January	2011	and	1	
January	2013.	Eligible	women	were	identified	by	cross‐referencing	





From	 the	 TeMpOH‐1	 database,	 we	 identified	 all	 women	who	were	
initially	managed	by	intrauterine	balloon	tamponade	or	uterine	artery	




with	 the	 administration	 of	 at	 least	 one	 uterotonic	 agent	 (including	
oxytocin	[prophylactic	use	of	oxytocin	following	childbirth	excluded],	
ergometrine,	misoprostol	or	 sulprostone).	By	using	 this	definition	of	
persistent	 postpartum	 hemorrhage,	 we	 avoided	 a	 definition	 solely	
based	on	mere	estimation	of	blood	loss	and	ensured	that	women	in‐



















(MNM)	tool	 to	enable	uniform	 identification	of	 those	women	who	
nearly	died	but	survived	a	complication	during	pregnancy,	childbirth	
or	within	42	days	of	 termination	of	pregnancy.16	 In	 this	approach,	
women	 who	 underwent	 peripartum	 hysterectomy	 due	 to	 hemor‐
rhage	are	considered	MNM.	The	reason	to	perform	uterine	balloon	









The	 propensity	 score,	 representing	 the	 probability	 of	 receiving	
intrauterine	 balloon	 tamponade	 during	 the	 course	 of	 persistent	
postpartum	 hemorrhage,	 was	 estimated	 by	 a	 logistic	 regression	







Characteristics	 included	as	 covariates	 that	were	available	at	 the	
moment	the	clinician	decided	to	use	intrauterine	balloon	tamponade	
or	perform	uterine	artery	embolization	were:	maternal	age,	gestational	



















and	 uterine	 artery	 ligation).	 These	 clinically	 relevant	 characteristics	
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orrhage	were	matched	with	women	with	 the same chance	 (ie,	 same	
propensity	 score)	 of	 receiving	 intrauterine	 balloon	 tamponade	 but	
who	underwent	uterine	artery	embolization	instead	within	the	same	








by	 standardized	 differences,	 where	 distributions	 of	 characteristics	
were	considered	comparable	when	the	standardized	difference	was	














as	a	covariate	 in	 the	 logistic	 regression	model	 to	compare	 the	pri‐





as	 frequencies	 with	 percentages	 (%).	 All	 statistical	 analyses	 were	
performed	using	the	STATA STATISTICAL SOFTWARE: Release 14 
(StataCorp	LP,	College	Station,	TX,	USA).	The	statistical	analysis	plan	
was	 approved	 by	 the	 Scientific	Committee	 of	 the	 Sanquin	Center	
for	Clinical	Transfusion	Research	before	execution	of	the	analyses.
2.5 | Ethical approval
The	TeMpOH‐1	 study	was	 approved	by	 the	 Ethical	Committee	 of	
Leiden	University	Medical	Center	 (P12.273;	31	January	2013)	and	
by	the	institutional	review	boards	of	all	participating	hospitals.	The	















373	women	who	 initially	 had	 intrauterine	 balloon	 tamponade,	 50	
were	propensity	score‐matched	with	50	of	82	women	who	initially	













embolization	 (median	 3500	 mL	 [IQR	 3000‐4500]).	 Furthermore,	











bleeding	was	adequately	 treated.	After	 intrauterine	balloon	 inser‐
tion,	12	women	 (3%)	had	a	B‐Lynch	suture,	 four	women	 (1%)	had	
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uterine	 artery	 ligation	 and	 81	 women	 (22%)	 still	 had	 to	 undergo	
uterine	artery	embolization,	7	of	whom	eventually	underwent	hys‐
terectomy.	The	total	number	of	women	who	had	a	peripartum	hys‐
terectomy	 after	 intrauterine	 balloon	 tamponade	was	 19	 (5%)	 and	




had	uterine	artery	 ligation	and	10	 (12%)	 required	peripartum	hys‐


















In	 the	 propensity	 score‐matched	 cohort,	 29	 of	 the	 50	women	
























sis.	When	 the	 propensity	 score	was	 used	 as	 the	 only	 covariate	 in	
the	logistic	regression	model	to	compare	the	primary	outcome	meas‐









This	 propensity	 score‐matched	 cohort	 study	 found	 no	 significant	
difference	in	the	risk	of	the	composite	outcome	of	peripartum	hys‐
terectomy	and/or	maternal	death	between	women	with	persistent	
F I G U R E  1  Flowchart	of	study	enrollment	and	propensity	score‐
matching.	IUBT,	intrauterine	balloon	tamponade;	UAE,	uterine	
artery	embolization








One	 woman	 suffered	 an	 embolization‐related	 thrombo‐embolic	
event.
To	 the	 best	 of	 our	 knowledge	 this	 is	 the	 first	 study	 compar‐
ing	the	effectiveness	of	intrauterine	balloon	tamponade	with	an‐
other	invasive	management	strategy	to	control	bleeding	and	avert	
peripartum	 hysterectomy	 and	 maternal	 death	 during	 persistent	
postpartum	hemorrhage.	By	using	propensity	score‐matching,	we	
TA B L E  1  Clinically	relevant	characteristics	for	women	who	had	intrauterine	balloon	tamponade	or	who	underwent	uterine	artery	
embolization	after	an	estimated	blood	loss	of	1000‐7000	mL	because	of	persistent	postpartum	hemorrhage	before	and	after	propensity	
score‐matching
Before PS matching After PS matching
IUBT (n = 373) UAE (n = 82) SMD (%) IUBT (n = 50) UAE (n = 50) SMD (%)
Maternal	age,	ya 31	(28‐35) 32	(29‐36) 15.6 32	(29‐37) 31	(29‐36) 5.7
Gestational	age,	wka 39	(38‐40) 38	(37‐40) 28.9 39	(37‐40) 38	(37‐40) 6.9
Multiparity,	n	(%) 170	(46) 43	(52) 16.8 28	(56) 27	(54) 4.0
Preeclampsia,	n	(%) 36	(10) 10	(12) 7.5 6	(12) 6	(12) .0
Multiple	pregnancy,	n	(%) 23	(6) 6	(7) 7.1 4	(8) 4	(8) .0
Prior	cesarean	birth,	n	(%) 44	(12) 16	(20) 22.4 9	(18) 10	(20) 5.0
Mode	of	birth,	n	(%)
Vaginal	delivery 300	(80) 49	(60) 54.0 28	(56) 28	(56) .0
Cesarean	section 73	(20) 33	(40) 22	(44) 22	(44)
Cause	of	hemorrhage,	n	(%)
Uterine	atony 293	(79) 53	(64) Ref 32	(64) 33	(66) Ref
Retained	placenta 45	(12) 7	(9) 6.6 5	(10) 5	(10) .0
Abnormally	invasive	placenta 24	(6) 7	(9) 19.2 6	(12) 6	(12) .0
Other	causes 11	(3) 15	(18) 34.7 7	(14) 6	(12) 5.9
Placental	abruption 2 1 — 2 0 —
Placenta	previa 2 3 — 2 1 —












Coagulopathy,	n	(%) 42	(11) 35	(43) 60.4 18	(36) 18	(36) .0
Symptoms	of	shock,	n	(%) 304	(82) 68	(83) 1.3 40	(80) 41	(82) 5.0
Number	of	uterotonics	givena 2	(2‐3) 2	(1‐3) 28.0 2	(1‐2) 2	(1‐3) 5.2
Non‐uterotonic	agents,	n	(%)
Tranexamic	acid 132	(35) 42	(51) 13.5 23	(46) 21	(42) 8.0
Fibrinogen	concentrate 6	(2) 13	(16) 30.0 4	(8) 4	(8) .0
Recombinant	factor	VIIa 3	(1) 3	(4) 10.1 1	(2) 1	(2) .0
Blood	componentsa
Packed	red	blood	cells 1	(0‐2) 4	(3‐7) 88.7 4	(2‐6) 4	(2‐5) 9.2
Fresh	frozen	plasma 0	(0‐1) 2	(1‐4) 80.1 2	(0‐2) 2	(0‐2) 5.5
Platelet	transfusion 0	(0‐0) 0	(0‐1) 48.7 0	(0‐0) 0	(0‐0) 6.3
Surgical	interventions,	n	(%) 3	(1) 2	(2) 20.8 2	(4) 2	(4) .0
B‐Lynch	suture 3 2 — 2 2 —
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ensured	 a	 similar	 distribution	of	 potential	 confounding	 variables	
between	 the	 intervention	 groups.	 The	 definition	 of	 persistent	
postpartum	hemorrhage	enabled	us	to	overcome	differences	be‐
tween	 caregivers	 regarding	 estimation	 of	 blood	 loss	 and	 estab‐
lish	 a	 clear	 point	 in	 time	 at	which	 an	 additional	 intervention	 (ie,	
intrauterine	 balloon	 tamponade	 or	 uterine	 artery	 embolization)	
was	 deemed	 necessary	 following	 failure	 of	 initial	 management.	
Another	 key	 strength	 is	 that	 the	 composite	 primary	 outcome	
consisted	 of	 two	 postpartum	 hemorrhage‐related	 core	 outcome	
sets	(peripartum	hysterectomy	and	maternal	death),	allowing	our	
results	 to	be	potentially	 included	 in	systematic	 reviews	or	meta‐
analyses	 on	 persistent	 postpartum	 hemorrhage.31	 Furthermore,	
the	 extensive	 TeMpOH‐1	 database	 made	 it	 possible	 to	 include	
many	 characteristics	 as	 potential	 confounders	 in	 the	 propensity	
score	 model.	 Nonetheless,	 even	 though	 this	 is	 the	 first	 study	
that	compares	the	effectiveness	of	 intrauterine	balloon	tampon‐
ade	with	 another	 invasive	management	 strategy,	 our	 propensity	
score‐matched	sample	size	was	 limited	to	50	pairs.	This	resulted	
in	confidence	intervals	too	broad	to	rule	out	type	II	error	for	the	











balloon	 tamponade	 or	 uterine	 artery	 embolization.	 Additionally,	
although	we	are	confident	that	we	have	included	all	clinically	rel‐
evant	 characteristics	 associated	with	 the	 clinical	 decision	 to	use	
intrauterine	 balloon	 tamponade	 or	 uterine	 artery	 embolization,	
residual	 confounding	 cannot	 be	 ruled	 out.	 Finally,	 women	 were	
included	when	in	need	of	four	or	more	units	of	packed	red	blood	
cells	 or	 a	multicomponent	 blood	 transfusion,	 with	 an	 estimated	
blood	loss	of	1000‐7000	mL	at	the	time	of	 intervention.	Our	re‐




Intrauterine	 balloon	 tamponade	 has	 been	 incorporated	 as	 a	
management	 option	 into	 multiple	 national	 guidelines	 for	 postpar‐
tum	hemorrhage.32‐35	 In	non‐comparative	studies,	success	rates	of	
intrauterine	balloon	tamponade	to	control	bleeding	after	childbirth	
varied	 between	 67%	 and	 91%.6,12,13,36	However,	 evidence	 for	 the	
benefits	 of	 intrauterine	 balloon	 tamponade	 compared	 with	 other	
invasive	management	strategies	 is	 lacking,	 resulting	 in	uncertainty	
about	whether	 intrauterine	balloon	 tamponade	 is	 effective	during	
the	course	of	persistent	postpartum	hemorrhage.37
Our	reported	success	rate	of	70%	among	all	women	who	were	

















































































































































































































































































































































































































































































































to	 control	 hemorrhage	was	 58%	 in	 the	 propensity	 score‐matched	
cohort.	The	explanation	for	this	apparent	lower	success	rate	could	
be	due	 to	 the	difference	 in	 severity	of	bleeding.	Volume	of	blood	
loss	at	time	of	intrauterine	balloon	insertion	was	lower	for	the	total	
cohort	 of	 women	 who	 had	 intrauterine	 balloon	 tamponade	 (me‐
dian	2500	mL	[IQR	2000‐3000])	than	for	women	in	the	propensity	
score‐matched	 cohort	 (median	 3250	 mL	 [IQR	 2500‐4000]).	 This	
is	because	we	matched	women	who	had	 intrauterine	balloon	tam‐
ponade	 with	 women	 who	 had	 uterine	 artery	 embolization	 within	
the	 same	 increment	of	 blood	 loss	 at	 the	 time	of	 the	 intervention.	










overestimation	of	 the	effectiveness	due	to	 the	possibility	 that	 the	
use	of	intrauterine	balloon	tamponade	was	not	absolutely	necessary.
Although	34%	of	women	who	initially	received	intrauterine	bal‐
loon	 tamponade	had	 an	 additional	 intervention,	 there	was	no	 sig‐
nificant	 difference	 in	 the	 risk	 of	 peripartum	 hysterectomy	 and	 or	
maternal	death	compared	with	women	who	initially	underwent	uter‐
ine	 artery	 embolization.	 Therefore,	 our	 results	 indicate	 that	 initial	
management	 by	 intrauterine	 balloon	 tamponade	 during	 persistent	
postpartum	hemorrhage	has	 the	potential	 to	 control	bleeding	and	
obviate	 the	 need	 for	 uterine	 artery	 embolization	 in	most	women,	
without	 an	 increased	 risk	 of	 severe	 maternal	 outcome.	 By	 using	
intrauterine	balloon	 tamponade	as	 the	 intervention	of	 first	 choice	










nal	mortality.	Furthermore,	 it	 is	specifically	 important	to	note	that	
if	 uterine	 artery	 embolization	was	not	 available,	 it	 is	 possible	 that	
a	larger	proportion	of	women	who	were	initially	managed	by	intra‐
uterine	 balloon	 tamponade	 had	 peripartum	hysterectomy	or	 died.	










uterine	 artery	 embolization	 is	 not	 widely	 available,	 comparative	




uated	 the	 effectiveness	 of	 intrauterine	 balloon	 tamponade	 as	 an	
adjunct	 to	misoprostol	 but	was	 underpowered	 to	 demonstrate	 a	
significant	treatment	effect.43	The	inability	to	resolve	the	research	
question	of	whether	intrauterine	balloon	tamponade	is	as	good	as	
or	 superior	 to	 other	management	 strategies	 due	 to	 small	 sample	
sizes,	highlights	the	need	for	larger	studies	comparing	intrauterine	
balloon	 tamponade	with	other	management	 strategies	 for	 a	 sub‐
stantiated	implementation	of	intrauterine	balloon	tamponade	into	
the	clinical	guidelines	for	management	of	postpartum	hemorrhage.	
International	 research	collaboration	may	be	 the	key	 to	overcome	
the	problem	of	 low	statistical	power	and	determine	whether	and	
when	 intrauterine	balloon	 tamponade	 should	be	used	during	 the	
course	 of	 postpartum	 hemorrhage.	 Our	 study	 design	 provides	 a	
useful	 framework	 and	 could	 serve	 as	 a	 starting	 point	 for	 future	
















options	 for	 a	 substantiated	 implementation	of	balloon	 tamponade	
into	clinical	guidelines	for	management	of	postpartum	hemorrhage.
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